



HUTCHISON CHINA MEDITECH LTD

**Hutchison China MediTech Limited (“Chi-Med”)  
(AIM: HCM)**

**Total Voting Rights**

**London: Monday, 5 July 2010:** For information purposes, Chi-Med hereby notifies the market that as at 30 June 2010, the issued share capital of the Company consisted of 51,734,618 ordinary shares of US\$1.00 each, with each share carrying one right to vote and with no shares held in treasury.

The above figure of 51,734,618 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Chi-Med under the FSA's Disclosure and Transparency Rules.

**Ends**

**Enquiries**

**Chi-Med**

Christian Hogg, CEO

Telephone: +852 2121 8200

**Citigate Dewe Rogerson**

Anthony Carlisle

David Dible

Telephone: +44 (0) 20 7638 9571

+44 (0) 7973 611 888

+44 (0) 7967 566 919

**Lazard & Co., Limited**

Paul Gismondi

Nick Fowler

Telephone: +44 (0) 20 7187 2000

**About Chi-Med**

Chi-Med is the holding company of a pharmaceutical and healthcare group based primarily in China and was admitted to trading on the Alternative Investment Market of the London Stock Exchange in May 2006. It is focused on researching, developing, manufacturing, and selling pharmaceuticals and health oriented consumer products.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited.